Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | Toxicity in Mus musculus Swiss albino (mouse) assessed as mortality at 25 mg/kg, po | ChEMBL. | No reference | |
Activity (functional) | = -29.78 % | Antidepressant activity in Mus musculus Swiss albino (mouse) assessed as duration of immobility at 25 mg/kg, ip measured after 1 hr by forced swim test test relative to pretreatment | ChEMBL. | No reference |
Activity (functional) | = 0 % | Anticonvulsant activity against maximal electroshock-induced seizures in Mus musculus Swiss albino (mouse) assessed as animals protected at 25 mg/kg | ChEMBL. | No reference |
Activity (functional) | = 46.93 % | Antidepressant activity in Mus musculus Swiss albino (mouse) assessed as as increase in mobile phase at 25 mg/kg, ip measured after 1 hr by tail suspension test | ChEMBL. | No reference |
TIME (functional) | = 6.18 s | Anticonvulsant activity against maximal electroshock-induced seizures in Mus musculus Swiss albino (mouse) assessed as time duration of tonic limb extensor at 25 mg/kg | ChEMBL. | No reference |
TIME (functional) | = 29.86 s | Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as time spent in open arm by elevated plus maze test | ChEMBL. | No reference |
TIME (functional) | = 81.74 s | Anticonvulsant activity against pentylenetetrazole-induced seizures in Mus musculus Swiss albino (mouse) assessed as onset of seizures at 25 mg/kg, po administered 1 hr prior challenge | ChEMBL. | No reference |
TIME (functional) | = 163 s | Anxiolytic activity in Mus musculus Swiss albino (mouse) assessed as time spent in light chamber at 25 mg/kg by light-dark box test | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.